| Over a week ago | ||||
Cantor Fitzgerald analyst… Cantor Fitzgerald analyst Ross Osborn lowered the firm's price target on Nyxoah to $12 from $17 and keeps an Overweight rating on the shares following the Q1 results. Nyxoah called out three headwinds during the quarter, which the company believes are transitory, including high volume accounts experienced seasonal reduction in OR capacity and newly activated accounts were slow to implant due to the administrative burden to clear procedure funding, the analyst tells investors in a research note. | ||||
Stifel analyst Jonathan… Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah to $15 from $16 and keeps a Buy rating on the shares. This is the third quarter in a row that Nyxoah missed the firm's top-line estimate, the analyst tells investors. While disconcerting, the "real prize" is the full submission of the PMA for its DREAM U.S. pivotal trial, which will take place after 12-month data is released in Q1 of 2024. While risks remain, if 12-month data is positive, the firm expects a favorable stock reaction. | ||||
Piper Sandler analyst… Piper Sandler analyst Adam Maeder lowered the firm's price target on Nyxoah to $12 from $13 and keeps an Overweight rating on the shares. The company reported Q1 revenue below expectations, which management attributed to limited access and seasonality pressures in both high-volume accounts and newly onboarded centers, the analyst tells investors in a research note. However, the company has made some nice operational progress over the past couple months, which helps set the foundation for future success, says Piper. | ||||
Reports Q1 revenue EUR… Reports Q1 revenue EUR 441M vs. EUR 660M last year. "In 2023, our focus is in the U.S. on DREAM patient follow up resulting in reaching the primary endpoints. I am excited by the data on the first 34 patients and look forward to sharing the full abstract results at SLEEP 2023 next month. Our increasing conviction in DREAM outcomes is accelerating investment in our commercial organization, starting with the addition of Christoph as Chief Commercial Officer," commented Olivier Taelman, Nyxoah's CEO. "Christoph's hire, along with the EUR 19 million raised from key investors, puts us in a strong position as we embark on our next stage of growth." | ||||
| Over a month ago | ||||
Nyxoah SA announced that… Nyxoah SA announced that the company raised $3.0M in gross proceeds pursuant to the company's $50M at-the-market program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The proceeds will be used for general corporate purposes. | ||||
Virtual Meeting to be… Virtual Meeting to be held on March 27 hosted by Piper Sandler. | ||||
Nyxoah announced a EUR… Nyxoah announced a EUR 13.35M private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of EUR 6.52, approximately U.S. $7.10 at current exchange rates, the closing price on Euronext Brussels on March 23, 2023. Gross proceeds total EUR 13.35M, approximately U.S. $15M at current exchange rates, and will be used for general corporate purposes. | ||||
Virtual Analyst &… Virtual Analyst & Investor Meeting to be held on March 23 at 4 pm. Webcast Link | ||||
Stifel analyst Jonathan… Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah to $16 from $19 and keeps a Buy rating on the shares. In the firm's opinion, the most important highlights from the company's recently released Q4 results was data on the first 34 DREAM patients. Currently, apnea-hypopnea index, API / oxygen-desaturation index, ODI, metrics are both above the "at least" 63% AHI/ODI responder rate needed for DREAM to be successful, Stifel tells investors. However, its Q4 revenue was below Street estimates and its market share in Germany has temporarily stalled in the low-30% range. | ||||
Virtual Analyst &… Virtual Analyst & Investor Meeting to be held on March 23 at 4 pm. Webcast Link | ||||
